Speakers: Umer Raffat, Evercore ISI
Organizers: Shichang Miao, PBSS
Date: 2024-10-28
Time: 11:00-12:30 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-10-27  (it will close sooner if the seating cap is reached)

About the Topic

The American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) annual conferences are two of the largest and most prestigious cancer research conferences. Numerous biotech and pharmaceutical companies showcase their latest results and they are important events for understanding the latest clinical trial results, innovative therapies and emerging trends. Join us to hear the highlights from Umer Raffat, one of the renowned investment analysts with deep expertise in the biotech and pharmaceutical sectors. His insights are highly valued by industry leaders, so don’t miss this rare opportunity to gain valuable perspectives from him.

Umer Raffat is a renowned and highly regarded Wall Street analyst in the biotech / pharmaceutical sectors. He is a senior managing director at Evercore ISI and heads the large-cap therapeutics effort spanning pharmaceuticals-major and specialty pharmaceuticals. As of 2023, Mr. Raffat has been ranked No. 1 on 19 separate occasions by Institutional Investor, starting from his first year covering the sector. Previously, he ranked as the No. 1 Rising Star Analyst for two years in a row. Most recently, he ranked No. 1 in both the biotechnology large-cap and specialty pharmaceuticals sectors, and No. 2 in major pharmaceuticals.

He started his equity research career under Dr. Mark Schoenebaum at Deutsche Bank in 2010, and they moved together to Evercore ISI. In 2020, Mr. Raffat was inducted into Institutional Investor’s All-America Research Team Hall of Fame, a designation for analysts who have earned a No. 1 ranking on at least 10 occasions. 

Mr. Raffat has an undergraduate degree in biology from University of Texas at Arlington and a master’s from Harvard School of Public Health.